VNOV VitaNova Life Sciences Corp
Wholesale-Apparel, Piece Goods & Notions · OTC · SEC CIK 1699709 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.0%
TTM net income YoY-113.3%
TTM EPS YoY—
Revenue 3-yr CAGR420.5%
Net income 3-yr CAGR—
Margins
Gross margin26.9%
Operating margin-2.7%
Net margin-3.5%
FCF margin—
EBITDA margin—
Returns
ROE-6.0%
ROA-5.1%
ROIC (approx.)-11.9%
Asset turnover1.45x
Leverage & solvency
Liabilities / assets13.9%
Debt / equity0.00x
Current ratio7.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.89x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-07-31 | 2026Q4*2026-04-30 | 2026Q32026-01-31 | 2026Q22025-10-31 | 2026Q12025-07-31 | 2025Q4*2025-04-30 | 2025Q32025-01-31 | 2025Q22024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $321,576 | $1.78M | $709,625 | $427,115 | $103,899 | $1.95M | $308,318 | $292,118 |
| Cost of revenue | $291,055 | $1.52M | $393,282 | $166,312 | $35,118 | $795,801 | $119,006 | $136,284 |
| Gross profit | $30,521 | $264,662 | $316,343 | $260,803 | $68,781 | $1.16M | $189,312 | $155,834 |
| SG&A expense | $114,831 | $328,457 | $219,600 | $119,444 | $66,293 | $29,775 | $30,667 | $40,107 |
| Operating income | -$122,162 | -$109,860 | $46,731 | $99,170 | -$32,440 | $1.08M | $108,874 | $62,600 |
| Interest expense | — | $0 | $0 | $0 | — | $1,568 | $813 | $2,125 |
| Pretax income | — | -$107,000 | $46,731 | $99,290 | -$32,440 | $1.08M | $108,257 | $60,775 |
| Income tax | $939 | -$124,549 | $91,093 | $63,480 | $13,861 | $280,354 | $35,279 | $28,128 |
| Net income | -$123,101 | $17,549 | -$44,362 | $35,810 | -$46,301 | $800,332 | $72,978 | $32,647 |
| EPS (basic) | -0.01 | — | -0.01 | 0.00 | -0.01 | — | 0.01 | 0.00 |
| EPS (diluted) | — | — | -0.01 | 0.00 | 0.00 | — | 0.01 | 0.00 |
| Weighted avg. shares (diluted) | — | — | 8.34M | 25.01M | 25.01M | — | 8.34M | 25.01M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.60M | $1.60M | $1.17M | $1.26M | $1.05M | $782,810 | $405,173 | $222,795 |
| Receivables | $316,871 | $726,743 | $1.00M | $882,612 | $1.01M | $1.27M | $54,018 | $57,700 |
| Inventory | $301,294 | $105,613 | $130,436 | $11,267 | $9,130 | $44,247 | $186,727 | $303,094 |
| Current assets | $2.22M | $2.43M | $2.31M | $2.34M | $2.24M | $2.26M | $1.32M | $1.26M |
| Total assets | $2.24M | $2.45M | $2.31M | $2.34M | $2.24M | $2.26M | $1.32M | $1.26M |
| Current liabilities | $311,656 | $395,781 | $457,975 | $438,051 | $379,975 | $347,567 | $212,789 | $223,938 |
| Total liabilities | $311,656 | $395,781 | $457,975 | $438,051 | $379,975 | $347,567 | $212,789 | $223,938 |
| Shareholders' equity | $1.93M | $2.05M | $1.85M | $1.90M | $1.86M | $1.91M | $1.11M | $1.03M |
| Shares outstanding | 8.34M | 8.34M | — | 25.01M | 25.01M | 8.34M | 25.01M | 25.01M |
| Cash flow statement | ||||||||
| Operating cash flow | $6,965 | $428,313 | -$90,377 | $212,661 | $263,811 | $479,137 | $208,878 | $8,760 |
| Financing cash flow | — | $0 | $0 | $0 | $0 | -$101,500 | -$26,500 | $72,400 |
| Stock-based compensation | — | $179,400 | $0 | $0 | $0 | $0 | $500 | $750 |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.